GlassScriptPhysician profile
Todd C Genre
NPI 1265604300
$3,686.25
in general payments reported to CMS, 2019-2025
22 companies · $539 in 2025
The $539 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $919 · 2022: $482 · 2023: $949 · 2024: $797 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,285.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $740.18 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $463.89 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Antares Pharma, INC. | $447.89 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Lilly USA, LLC | $439.55 | 2021-2025 | Jardiance, Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $403.90 | 2021-2025 | |
| Janssen Biotech, INC. | $224.75 | 2021-2022 | |
| Exact Sciences Corporation | $147.64 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $119.33 | 2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.55 | 2021-2024 | Jardiance, Synjardy |
| Sumitomo Pharma America, INC. | $97.46 | 2023 | Gemtesa |
| Jazz Pharmaceuticals INC. | $88.51 | 2021-2022 | |
| Glaxosmithkline, LLC. | $74.84 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $69.54 | 2021 | |
| Abbvie INC. | $58.30 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $55.87 | 2021-2024 | Farxiga |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $40.90 | 2023-2024 | |
| Acerus Pharmaceuticals Corporation | $33.78 | 2021 | |
| Halozyme INC | $21.56 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.14 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.25 | 2024 | Keveyis |
| Eisai INC. | $14.90 | 2022 | |
| Merck Sharp & Dohme LLC | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Genre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.